AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31547713
Drug: Cluster immunotherapy
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster immunotherapy in adults
Trial: 27647770
Drug: Ormeloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ormeloxifene (60 mg twice per week)
Trial: 27647770
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptive (ethinyl estradiol 30 μg with desogestrel 150 μg on days 1-21 for 6 months)
Trial: 23059433
Drug: Active reflexology
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active reflexology treatment to areas of the feet corresponding to the heart
Trial: 23059433
Drug: Control reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control reflexology treatment to other areas of the feet
Trial: 11960019
Drug: Biological motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological motion stimulus based on a limited lifetime technique
Trial: 12452304
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (group 1)
Trial: 29040268
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (goal systolic pressure < 120 mm Hg)
Trial: 23563218
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (supportive therapy)
Trial: 21440734
Drug: Low-dose rabbit
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose rabbit antithymocyte globulin (LoD-rATG, 3-5 mg/kg)
Trial: 21440734
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of rabbit antithymocyte globulin (7-10 mg/kg)
Trial: 16909140
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus irinotecan (IG) - 300 mg m(‐2) on day 8, gemcitabine on days 1 and 8, repeated every 3 weeks.
Trial: 16909140
Drug: Gemcitabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine monotherapy (G) - 900 mg m(‐2) on days 1, 8, and 15 every 4 weeks.
Trial: 11426345
Drug: Polypharmacy cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy cream (testosterone 0.8%, isosorbide dinitrate 0.5%, co‐dergocrine mesylate 0.06%)
Trial: 11426345
Drug: Testosterone cream
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream (0.8%)
Trial: 10965083
Drug: Nitrolingual-Spray
RxNorm normalized name: nitroglycerin Mucosal Spray [Nitrolingual]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrolingual-Spray
Trial: 10965083
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) tablets
Trial: 8981709
Drug: Combined temporal
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined temporal corneal phacoemulsification and superior trabeculectomy with low-dose 5-FU
Trial: 8981709
Drug: Trabeculectomy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy alone with low-dose 5-FU
Trial: 1290475
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of oral enterically coated 4‐aminosalicylic acid
Trial: 26531051
Drug: Topical natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical natamycin or voriconazole (corrected for treatment arm)
Trial: 24523562
Drug: D1-like receptor
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-like receptor activation with l-DOPA (25 mg)
Trial: 24523562
Drug: D1-like receptor
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-like receptor activation with l-DOPA (100 mg)
Trial: 24523562
Drug: D1-like receptor
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-like receptor activation with l-DOPA (200 mg)
Trial: 17438710
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy and radiotherapy
Trial: 16239090
Drug: Extended-release clarithromycin
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release clarithromycin (CLA-ER) 1000 mg once a day for 5 days
Trial: 16239090
Drug: Telithromycin (TELI)
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin (TELI) 800 mg once a day for 5 days
Trial: 10223677
Drug: Indirect therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect therapy (group 2)
Trial: 10223677
Drug: Direct with
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct with indirect therapy (group 3)
Trial: 10223677
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group 1)
Trial: 22366535
Drug: l‐dopa alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐dopa alone
Trial: 22366535
Drug: STN‐DBS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STN‐DBS plus l‐dopa
Trial: 22366535
Drug: Without STN‐DBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without STN‐DBS and without l‐dopa
Trial: 22366535
Drug: Reflex blinking
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflex blinking (STN‐DBS and l‐dopa)
Trial: 19022007
Drug: Prophylactic low-energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low-energy shock wave therapy (SWT) applied to the site of vein harvesting after wound closure (n = 50)
Trial: 12185103
Drug: CPA‐5‐100 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA‐5‐100 (5 mg/day CPA + 100 mg/week TE)
Trial: 12185103
Drug: CPA‐5‐200 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA‐5‐200 (5 mg/day CPA + 200 mg/week TE)
Trial: 1992688
Drug: Iodide salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodide salt administered to group A (n = 17)
Trial: 19321400
Drug: Bladder pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder pressure measurement (BP) using 50 mL of sterile saline instilled into the bladder, measured in the supine position.
Trial: 17257473
Drug: Oxymorphone extended
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone extended release (5- to 10-mg increments every 12 h, every 3-7 days)
Trial: 11599506
Drug: HMB in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB in time release capsule (TRH)
Trial: 8303754
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate at 0.6 mg/kg per day
Trial: 8303754
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate at 2.0 mg/kg per day
Trial: 8303754
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate at 6.0 mg/kg per day
Trial: 8303754
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of Tirilazad
Trial: 23652908
Drug: tretinoin plus
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tretinoin plus topical corticosteroids
Trial: 23652908
Drug: vehicle plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle plus topical corticosteroid
Trial: 21910803
Drug: Anti-TNF-α treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α treatment
Trial: 16055455
Drug: Non-NSAID (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-NSAID (paracetamol and codeine)
Trial: 12532174
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg s.c./24 h
Trial: 7480564
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of RS 15385
Trial: 7480564
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of RS 15385
Trial: 2257249
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment for 1 year
Trial: 2257249
Drug: Estro-progestative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estro-progestative treatment for 1 year
Trial: 2257249
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens treatment for 6 months post-oophorectomy
Trial: 24137971
Drug: Ascoril (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascoril (combined broncholytic and expectorant drug)
Trial: 24137971
Drug: Ambroxol (mucolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (mucolytic agent)
Trial: 20193328
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of pirarubicin (THP) at 1 hour before TUR-BT (30 mg/50 ml, 0.5 hours)
Trial: 20193328
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of pirarubicin (THP) at 24 hours before TUR-BT (30 mg/50 ml, 0.5 hours)
Trial: 17426207
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg) for 12 weeks
Trial: 7911736
Drug: Cladribine 4
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine 4 mg/m2/day
Trial: 7911736
Drug: Cladribine 6
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine 6 mg/m2/day
Trial: 7911736
Drug: Cladribine 8
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine 8 mg/m2/day
Trial: 28315160
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) at 2.0 g kg-1 of the diet for 4 weeks prior to MCLR injection
Trial: 28315160
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) at 1.0 g kg-1 of the diet for 4 weeks prior to MCLR injection
Trial: 28315160
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) at 0.5 g kg-1 of the diet for 4 weeks prior to MCLR injection
Trial: 28315160
Drug: MCLR intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCLR intraperitoneal injection (150 μg kg-1 BW)
Trial: 26289437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tastants (quinine, rebaudioside A, monosodium glutamate)
Trial: 19690450
Drug: Bathing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bathing with clear water twice weekly (Group B)
Trial: 19690450
Drug: Washing with
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washing with a washcloth moistened with clear water twice weekly (Group W)
Trial: 11097666
Drug: Air group
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air group (2 mL of air)
Trial: 11097666
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group (2 mL of 0.9% saline)
Trial: 9357887
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 0 ng/ml
Trial: 9357887
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 25 ng/ml
Trial: 9357887
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 50 ng/ml
Trial: 9357887
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 100 ng/ml
Trial: 9357887
Drug: Alfentanil administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil administration
Trial: 8211353
Drug: Aggressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive therapy for myocardial ischemia and infarction in elderly patients
Trial: 28956535
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants with platelet rich fibrin (PRF)
Trial: 28956535
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants without PRF (control)
Trial: 28956535
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants with PRF
Trial: 23116485
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg) with FF/VI (200/25 μg)
Trial: 18847427
Drug: Low-dose corticoids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticoids
Trial: 18847427
Drug: Anti-TNF-alpha agents
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-alpha agents
Trial: 2968263
Drug: doxifluridine 4000
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: doxifluridine 4000 mg/m2
Trial: 2968263
Drug: fluorouracil 450
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluorouracil 450 mg/m2 i.v.
Trial: 28364493
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (N = 26)
Trial: 28364493
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (N = 30)
Trial: 26567275
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of treadmill and lower-limb resistance supervised exercise training (SET) for 12 weeks
Trial: 25123230
Drug: internet-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based self-help problem solving treatment (PST) for affective symptoms
Trial: 22365697
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular.
Trial: 22365697
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular, based on bursal size.
Trial: 19732200
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose chemotherapy (SC)
Trial: 17101267
Drug: Expanding collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expanding collagen tablets
Trial: 17101267
Drug: Small sustained
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small sustained release hydrocolloid tablets
Trial: 15010336
Drug: 6‐h continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐h continuous infusion of [1,2‐(13)C(2)]taurine (3.1 +/- 0.2 micromol x kg(‐1) x h(‐1))
Trial: 15010336
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of [(13)C(2)]taurine (3.0 +/- 0.1 micromol/kg)
Trial: 15010336
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of tracer
Trial: 9610692
Drug: 5-fluorouracil (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (370 mg/m2) plus folinic acid (200 mg/m2) administered daily for 5 days every 4 weeks for 6 cycles
Trial: 7601177
Drug: Flurbiprofen LATTM
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen LATTM (40 mg) applied via a nonwoven polyester patch every 12 hours for 14 days
Trial: 7601177
Drug: Placebo (patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (patch without active ingredient)
Trial: 29401546
Drug: Levothyroxine and
RxNorm normalized name: Levothyroxine and liothyronine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine and iodide therapy
Trial: 23795985
Drug: IV ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV ranibizumab (0.5 mg, 0.05 cc)
Trial: 23795985
Drug: IV bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV bevacizumab (1.5 mg, 0.06 cc)
Trial: 19752567
Drug: Intranasal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal lavage with hypertonic saline solution 3 times daily
Trial: 19752567
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no local therapy)
Trial: 12030615
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg dexamethasone
Trial: 2142700
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg dexamethasone
Trial: 12030615
Drug: Dexamethasone administration
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administration at 21:00 h vs 23:00 h
Trial: 367255
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate (Resibion) 500 mg
Trial: 367255
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate (Resibion) 250 mg every 6 hours
Trial: 367255
Drug: Enteric-coated erythromycin
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated erythromycin base (Etromycin) 250 mg every 6 hours
Trial: 24733648
Drug: Physiotherapy added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy added to standard treatment (deep breathing exercises, mobilizations, incentive spirometry)
Trial: 24733648
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (medical treatment and drainage)
Trial: 20819541
Drug: Sucrose gel
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose gel
Trial: 16466166
Drug: Fuzheng Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Huayu Capsule (FHC)
Trial: 9055715
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily for eight weeks plus amoxycillin 750 mg twice daily for weeks 7 and 8
Trial: 8396084
Drug: Dicloxacillin 250
RxNorm normalized name: dicloxacillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicloxacillin 250 mg four times a day for seven days
Trial: 3729711
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin sodium and metronidazole
Trial: 3729711
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G sodium, streptomycin, and metronidazole
Trial: 29407540
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus exercise (S+EX)
Trial: 29407540
Drug: Sertraline (S)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (S)
Trial: 25204412
Drug: Chemoradiation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation group (additional radiotherapy, second-line chemotherapy, or both)
Trial: 22288725
Drug: Low-dose azithromycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose azithromycin (250 mg orally daily for 5 days then 2× weekly for a total of 12 weeks)
Trial: 18551087
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise and hormone therapy (estradiol valerate 1 mg/d orally)